Condition: Metastatic Colorectal Cancer · Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.
This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.
This description comes directly from the study's public registry record.
Mingfei Zhang · +8618621952423 · mfzhang@epimab.com
Junqiang He · +8618302157016 · jqhe@epimab.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| The Sixth Affiliated Hospital of Sun Yat-Sen University | Guangzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07314294